198 results
8-K
EX-99.1
KA
Kineta Inc
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose …
Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors
8-K
EX-99.1
KA
Kineta Inc
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
Favorable clinical safety and tolerability … cytokines and chemokines
Dose-dependent increases in activated non-classical monocytes, CD4+ and CD8+ T cells, and NK cells
Safety
No DLTs observed
8-K
EX-99.1
ti9hj5hmtb117je8n73e
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
EX-99.1
nb4oe0t6e1e5b
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.2
ahfjz5noo t2rlcr3
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.1
43feboijfc ikhrhfr5
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
EX-99.1
6lxoyufq82a
5 Jan 24
Regulation FD Disclosure
4:30pm
8-K
w81cwj4
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.2
1xhu5x7
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
65um3grj7v v7elff
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
loscn8be wt2bak4
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.2
notwu
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
ag5ehg77p95za9fp
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.1
7zv8k tgp
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-10.1
tghp89f3tkkrospfm
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
u8r1dii1ow7n2wri1v35
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am